Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

Presentation TCT India 2025

Renal Denervation: Patient Selection/Technical Aspects

Presenter: Ajay J. Kirtane

July 27, 2025

Presentation TCT India 2025

Renal Denervation: Patient Selection/Technical Aspects

Presenter: Ajay J. Kirtane

July 26, 2025

Presentation Miami Valves 2025

Initial Experience with the Symplicity Spiral Catheter for Renal Artery Denervation in the Dominican Republic

Presenter: Marcos Domínguez Vargas

January 30, 2025

Presentation ACC 2024

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Presenter: David E. Kandzari

April 08, 2024

Presentation Controversies and Advances 2023

Renal Denervation Will Be an Option for Most Hypertensive Patients!

Presenter: Michael J. Bloch

November 30, 2023

Presentation EuroPCR 2023

Effectiveness and Safety of the NetrodTM Six-Electrode Radiofrequency Renal Denervation System for the Treatment of Uncontrolled Essential Hypertension

Presenter: Yu-Jie Zhou

May 17, 2023

Presentation Miami Valves 2023

What’s New In Renal Denervation?

Presenter: Sergio Perez

February 04, 2023

Presentation AHA 2022

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Presenter: David E. Kandzari

November 07, 2022

Presentation EuroPCR 2022

Blood pressure and MACE reductions after renal denervation: 3-year GSR results

Presenter: Felix Mahfoud

May 20, 2022

Presentation ARCH 2022

Current Status and Future of Renal Denervation for Hypertension

Presenter: Tim A. Fischell

April 23, 2022

Presentation ACC 2022

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

Presenter: Felix Mahfoud

April 04, 2022

Presentation ACC 2021

Ultrasound Renal Denervation for Hypertension Resistant to a Triple Medication Pill: The Randomized Sham Controlled RADIANCE-HTN TRIO Trial

Presenter: Ajay J. Kirtane

May 16, 2021

Presentation ARCH 2019

Renal Denervation: Update of Trials

Presenter: Jason Fontana

April 12, 2019

Presentation CIT 2019

Where I See the Ideal Role for Renal Denervation Therapies

Presenter: Tony Walton

March 28, 2019

Presentation EuroPCR 2018

Renal Denervation in the Presence of Antihypertensive Medications: Six-month Results from the Randomized, Blinded, Sham-controlled SPYRAL HTN-ON MED Trial

Presenter: David E. Kandzari

May 23, 2018

Presentation Controversies and Advances 2017

Rise, Fall And Resurrection of Renal Denervation

Presenter: Michael A. Weber

November 16, 2017

Advertisement

Renal Denervation: Patient Selection/Technical Aspects

Renal Denervation: Patient Selection/Technical Aspects

Initial Experience with the Symplicity Spiral Catheter for Renal Artery Denervation in the Dominican Republic

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Renal Denervation Will Be an Option for Most Hypertensive Patients!

Effectiveness and Safety of the NetrodTM Six-Electrode Radiofrequency Renal Denervation System for the Treatment of Uncontrolled Essential Hypertension

What’s New In Renal Denervation?

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Blood pressure and MACE reductions after renal denervation: 3-year GSR results

Current Status and Future of Renal Denervation for Hypertension

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

Ultrasound Renal Denervation for Hypertension Resistant to a Triple Medication Pill: The Randomized Sham Controlled RADIANCE-HTN TRIO Trial

Renal Denervation: Update of Trials

Where I See the Ideal Role for Renal Denervation Therapies

Renal Denervation in the Presence of Antihypertensive Medications: Six-month Results from the Randomized, Blinded, Sham-controlled SPYRAL HTN-ON MED Trial

Rise, Fall And Resurrection of Renal Denervation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content